Full Year 2023 Investor Presentation

51 Investor presentation Full year 2023 Novo Nordisk global insulin market leadership at 45.4% and the global insulin volume market declined by 2% North America Operations Market growth: -3.7% MS: 37.2% MS gain/loss¹: -1.3%-p Sales growth: -23% USA Market growth: -3.9% MS: 37.0% MS gain/loss: -1.1%-p Sales growth: -25% Global Market growth: -2.0% MS 45.4% MS gain/loss: -1.3%-p Sales growth: -6% Novo NordiskⓇ International Operations Market growth: -1.5% MS: 48.0% MS gain/loss¹: -1.3%-p Sales growth: 0% Market growth: -3.5% MS: 57.7% MS gain/loss¹: +1.3%-p Sales growth: 4% Region China Market growth: 0.4% MS: 40.2% MS gain/loss: -8.3%-p Sales growth: -7% EMEA Market growth: -1.4% MS: 47.3% ROW MS gain/loss: +0.1%-p Sales growth: 3% 1MS gain/loss compared with Nov 2022 reported MS EMEA: Europe, Middle East and Africa; MS: Market share; ROW: Asia Pacific; Latin America; MS: Market Share; Region China covers Mainland China, Taiwan, and Hong Kong; Market values are based on the list prices Note: Sales growth for the full year 2023 at constant exchange rates; Market shares are for Novo Nordisk, market growth for total insulin market Source: IQVIA MAT, Nov 2023 volume figures

View entire presentation